StreetInsider.com News Articles

Form SCHEDULE 13D/A Alaunos Therapeutics, Filed by: Postma Robert W

Thu, 15 Oct 2026 19:55:00 -0400

si-local-file:///var/storage/secattach/20261015/27194483.html

Form 3 Alaunos Therapeutics, For: Oct 13 Filed by: Fairmount Funds Management LLC

Thu, 15 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261015/27193407.html

Form SCHEDULE 13D Alaunos Therapeutics, Filed by: Fairmount Funds Management LLC

Thu, 15 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261015/27193272.html

Alaunos acquires Velaris Therapeutics in $350M private placement deal

Tue, 13 Oct 2026 10:31:46 -0400

Alaunos Therapeutics (NASDAQ: TCRT) has completed the acquisition of Velaris Therapeutics, a privately held biotechnology company developing therapies for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases, according to a press release from the company.

Concurrent with the acquisition, Alaunos closed an oversubscribed private placement of Series C non-voting convertible preferred stock, raising approximately $350 million in gross proceeds. The round was led by Fairmount, with participation from Venrock Healthcare Capital Partners, T. Rowe Price Investment Management, Wellington Management, Janus Henderson Investors, BB Biotech, Perceptive Advisors, and others. The funding is expected to support operations into 2029.

Velaris's pipeline includes VLR199, an

Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics

Tue, 13 Oct 2026 10:31:00 -0400

Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension

Velaris Therapeutics, the ninth company launched based on Paragon-discovered assets, is advancing a pipeline built to address growth signaling imbalances that drive pulmonary vascular remodeling in PAH and secondary pulmonary hypertension (PH), including PH due to heart failure with preserved ejection fraction

Velaris is developing a broad pipeline of ActRII-Fcs and an anti-PDGF-B antibody, designed to be developed as monotherapies or in combination, across cardiopulmonary indications

The Company is expected to

Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics

Tue, 13 Oct 2026 10:31:00 -0400

Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension

Velaris Therapeutics, the ninth company launched based on Paragon-discovered assets, is advancing a pipeline built to address growth signaling imbalances that drive pulmonary vascular remodeling in PAH and secondary pulmonary hypertension (PH), including PH due to heart failure with preserved ejection fraction

Velaris is developing a broad pipeline of ActRII-Fcs and an anti-PDGF-B antibody, designed to be developed as monotherapies or in combination, across cardiopulmonary indications

The Company is expected to

Form 8-K Alaunos Therapeutics, For: Oct 13

Tue, 13 Oct 2026 09:29:00 -0400
si-local-file:///var/storage/secattach/20261013/27178827.html

Alaunos acquires Velaris Therapeutics; Paragon Labs adds new leaders

Tue, 13 Oct 2026 07:04:59 -0400

Alaunos Therapeutics, Inc. (NASDAQ: TCRT) has completed the acquisition of Velaris Therapeutics, Inc., a privately held biotechnology company developing therapies for pulmonary arterial hypertension and related cardiopulmonary diseases, according to a press release from Paragon Labs.
Velaris holds a portfolio of ActRII-Fc ligand traps and complementary biologics aimed at addressing signaling imbalances that drive remodeling of the pulmonary vasculature. Its assets were discovered by Paragon Labs, a Waltham, Massachusetts-based biologics company founded in 2021 by investment firm Fairmount.
Separately, Paragon Labs announced that several former senior executives from Apogee Therapeutics have joined its leadership team. The group is led by Michael Henderson,

Alaunos acquires Velaris Therapeutics; Paragon Labs adds new leaders

Tue, 13 Oct 2026 07:04:59 -0400

Alaunos Therapeutics, Inc. (NASDAQ: TCRT) has completed the acquisition of Velaris Therapeutics, Inc., a privately held biotechnology company developing therapies for pulmonary arterial hypertension and related cardiopulmonary diseases, according to a press release from Paragon Labs.
Velaris holds a portfolio of ActRII-Fc ligand traps and complementary biologics aimed at addressing signaling imbalances that drive remodeling of the pulmonary vasculature. Its assets were discovered by Paragon Labs, a Waltham, Massachusetts-based biologics company founded in 2021 by investment firm Fairmount.
Separately, Paragon Labs announced that several former senior executives from Apogee Therapeutics have joined its leadership team. The group is led by Michael Henderson,

Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.

Tue, 13 Oct 2026 07:00:00 -0400

Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie

Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership team

BOSTON, Oct. 13, 2026 /PRNewswire/ -- Paragon Labs

Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.

Tue, 13 Oct 2026 07:00:00 -0400

Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie

Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership team

BOSTON, Oct. 13, 2026 /PRNewswire/ -- Paragon Labs

Form 8-K Alaunos Therapeutics, For: Oct 05

Fri, 09 Oct 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20261009/27171865.html

Form 4 Alaunos Therapeutics, For: Oct 06 Filed by: Jerman Michael Allen

Thu, 08 Oct 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20261008/27167333.html

Form 4 Alaunos Therapeutics, For: Oct 06 Filed by: Vieser Jaime

Thu, 08 Oct 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20261008/27167351.html

Form 4 Alaunos Therapeutics, For: Oct 06 Filed by: Postma Robert W

Thu, 08 Oct 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20261008/27167357.html

Form 4 Alaunos Therapeutics, For: Oct 06 Filed by: Weis Holger

Thu, 08 Oct 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20261008/27167360.html

Form 8-K Alaunos Therapeutics, For: Sep 18

Tue, 22 Sep 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260922/27091433.html

Form 424B3 Alaunos Therapeutics,

Mon, 21 Sep 2026 17:04:00 -0400
si-local-file:///var/storage/secattach/20260921/27085964.html

Alaunos Therapeutics prices direct offering at $1.46 per share

Fri, 18 Sep 2026 09:00:55 -0400

Alaunos Therapeutics, Inc. (Nasdaq: TCRT) announced a registered direct offering priced at-the-market under Nasdaq rules, involving the sale of 380,469 shares of common stock and pre-funded warrants to purchase up to 386,654 shares of common stock at $1.46 per share.

The offering is expected to generate aggregate gross proceeds of approximately $1,120,000 before placement agent fees and other expenses. The company said it intends to use net proceeds primarily for general working capital and corporate purposes.

The offering is expected to close on or about September 21, 2026, subject to customary closing conditions. Dawson James Securities, Inc. is serving as the sole

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules

Fri, 18 Sep 2026 09:00:00 -0400

FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced that it has entered into definitive agreements with institutional investors in a registered direct offering for the sale of 380,469 shares of its common stock and pre-funded warrants to purchase up to 386,654 shares of common stock at a price of $1.46 per share, for aggregate gross proceeds of approximately $1,120,000, before deducting placement agent fees and offering expenses. The offering was priced at-the-market under Nasdaq rules. The offering is expected to close on or about September 21, 2026, subject to

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules

Fri, 18 Sep 2026 09:00:00 -0400

FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced that it has entered into definitive agreements with institutional investors in a registered direct offering for the sale of 380,469 shares of its common stock and pre-funded warrants to purchase up to 386,654 shares of common stock at a price of $1.46 per share, for aggregate gross proceeds of approximately $1,120,000, before deducting placement agent fees and offering expenses. The offering was priced at-the-market under Nasdaq rules. The offering is expected to close on or about September 21, 2026, subject to

Form 8-K Alaunos Therapeutics, For: Sep 16

Thu, 17 Sep 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260917/27072276.html

Form 10-Q Alaunos Therapeutics, For: Jun 30

Fri, 14 Aug 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260814/26931678.html

Form 10-Q Alaunos Therapeutics, For: Jun 30

Fri, 14 Aug 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260814/26931678.html

Form 4 Alaunos Therapeutics, For: Aug 06 Filed by: Weis Holger

Tue, 11 Aug 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260811/26905908.html